UCB, a multinational biopharmaceutical company, presented the first 4-year efficacy and safety data of the monoclonal antibody bimekizumab in the treatment of adults with moderate to severe plaque psoriasis during the annual meeting of the American Academy of Dermatology. “We are proud to present the 4-year data of bimekizumab on psoriasis at the most important dermatology congress in the world – states Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of US of UCB – demonstrating that the majority of adult patients treated with this drug achieved a deep and durable clinical response for up to 4 years, with a tolerability profile consistent with previous studies. These results, from the largest pool of phase 3 data, closely follow the US launch reinforce our belief that bimekizumab has the potential to improve the lives of people with moderate to severe plaque psoriasis.”
Moderate to severe plaque psoriasis is a “chronic condition with skin manifestations that can significantly negatively impact the patient's quality of life – explains Bruce Strober, clinical professor of Dermatology at Yale University and Central Connecticut Dermatology – L Analysis shows that, over 4 years of treatment with bimekizumab, more than 6 out of 10 patients achieved and maintained complete skin clearance, a clinically significant endpoint and an excellent patient outcome. These long-term data will be welcomed highly favored by the dermatology community, as they provide important considerations for clinical practice.”
The late breaking presentation – reports the note – shared the bimekizumab data collected from the start of treatment up to 4 years – reports a UCB note – demonstrating that high percentages of clinical response and quality of life related to the treatment were rapidly achieved health, maintained in the long term. The results showed that approximately 9 out of 10 patients treated with bimekizumab achieved a greater than 90% improvement from baseline in the Psoriasis Severity Index (Pasi90) and more than 7 out of 10 patients achieved complete clearance (Pasi100) at week 16. Responses which they then maintained until the fourth year. Analysis of pooled data from 5 Phase 3/3b studies showed that bimekizumab demonstrated a safety profile consistent with previous studies, with no new safety data identified for up to 4 years, in patients with moderate to moderate plaque psoriasis. serious.
Bimekizumab is a humanized IgG1 monoclonal antibody designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines underlying inflammatory processes. In the US it is approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The approved indications for bimekizumab in the European Union are: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis (alone or in combination with methotrexate to treat the disease in adults who have had an inadequate response or are intolerant to one or more Dmard disease-modifying antirheumatic drugs); active non-radiographic axial spondyloarthritis, with objective signs of inflammation, who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs); treatment of adults with active ankylosing spondylitis, who have responded inadequately or are intolerant to standard therapy.
#Psoriasis #years #bimekizumab #patients #complete #skin #clearance
